RAPT Therapeutics RAPT 深 沪
已收盘 10-24 16:00:00 美东时间
29.53
-0.470
-1.57%
华盛通- 最 高30.00
- 今 开29.75
- 成交量 55.51万股
- 最 低 28.865
- 昨 收 30.00
- 总市值 4.88亿
- 52周最高 42.3918
- 市盈率 静 --
- 换手率 3.36%
- 52周最低 5.6656
- 委 比 -60.00%
- 总股本 1653.78万
- 历史最高 409.68
- 量 比 0.33
- 振 幅 3.78%
- 历史最低 5.6656
- 每 手 1
- 风险率 6.06%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 富国银行上调苹果目标价升至290美元；"卖出"！花旗下调NuScale Power、阿特斯太阳能评级
今日重点评级关注：摩根大通：维持Cogent Biosciences"超配"评级，目标价从30美元升至44美元；Piper Sandler：维持Vital Energy"中性"评级，目标价从16美元升至30美元
10-22 10:10
RAPT Therapeutics announces proposed public offering
RAPT Therapeutics (NASDAQ:RAPT) announced on Tuesday that it has commenced an underwritten public offering of shares of its common stock. The company will grant the underwriters a 30-day purchase opt...
10-22 04:17
RAPT Therapeutics Announces Common Stock Offering; Terms Not Disclosed
RAPT Therapeutics, Inc. (NASDAQ:RAPT) ("RAPT"), a clinical-stage immunology-based biopharmaceutical company focused on discovering, developing and commercializing novel therapies for patients living with inflammatory and
10-22 04:02
RAPT Therapeutics Announces Proposed Public Offering of Common Stock
RAPT Therapeutics, Inc. has initiated an underwritten public offering of its common stock, with an option for underwriters to purchase up to an additional 15% of shares. The offering, subject to market conditions, is expected to be made pursuant to a shelf registration statement filed with the SEC. Leerink Partners, TD Cowen, Guggenheim Securities, Wells Fargo Securities, and LifeSci Capital are acting as joint bookrunning managers. The offering'...
10-21 20:01
美股大行评级 | 潜在涨幅344.44%！Rani Therapeutics获Maxim Group升目标价至10美元，维持"买入"评级
今日重点评级关注：Maxim Group：维持Rani Therapeutics Hldgs"买入"评级，目标价从5美元升至10美元；韦德布什：维持Corbus Pharmaceuticals"跑赢大市"评级，目标价从31美元升至38美元
10-21 18:13
12 Health Care Stocks Moving In Monday's Intraday Session
Gainers Replimune Group (NASDAQ:REPL) shares rose 119.1% to $9.86 during Monda...
10-21 02:39
RAPT Therapeutics to Report Topline Data from Phase 2 Clinical Trial of RPT904 in Chronic Spontaneous Urticaria (CSU)
RASTherapeutics宣布将于10月20日发布其合作伙伴上海杰优医药开发的RPT904在慢性自发性荨麻疹患者中进行的II期临床试验顶线数据，并举行网络研讨会，提供电话和网络接入方式。公司简介及联系方式随附。
10-19 12:00
Rapid7 Celebrates 7th Year of Recognition in Gartner® Magic Quadrant™ for Security Information and Event Management (SIEM)
Rapid7连续第七年入选Gartner SIEM魔力象限，展示了其在安全信息和事件管理领域的领导地位。其SIEM解决方案InsightIDR以整合检测和响应生态系统著称，专为提升安全团队效率设计。Rapid7最近推出的AI原生SIEM——Incident Command，结合Agentic AI工作流程，进一步增强了威胁检测和响应能力。该解决方案的亮点包括跨攻击面的可见性和协作、嵌入式威胁情报以及自动化响应功能。Rapid7通过不断的技术创新和扩展功能，致力于帮助客户更快检测威胁，减少疲劳感，并统一调查流程，以实现更高效的网络安全管理。
10-15 16:30
美股大行评级 | NTSK、STUB、WBI获多个机构首予评级；高盛上调雅诗兰黛(EL)评级至"买入"，目标价从76美元升至115美元
今日重点评级关注：花旗：维持Arcus Biosciences"买入"评级，目标价从47美元升至54美元；HC Wainwright & Co.：上调Karyopharm Therapeutics评级至"买入"，目标价15美元
10-14 09:56
Barclays Initiates Coverage On RAPT Therapeutics with Overweight Rating, Announces Price Target of $35
Barclays analyst Etzer Darout initiates coverage on RAPT Therapeutics (NASDAQ:RAPT) with a Overweight rating and announces Price Target of $35.
10-13 20:12
